Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APR-246 with Cisplatin and 5-FU in Platinum-Resistant Esophageal Cancer
NCT02999893Phase 2Terminated
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Apr 2017
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eprenetapopt in esophageal carcinoma, gastroesophageal junction adenocarcinoma, sponsored by Peter MacCallum Cancer Centre. Started Apr 2017; status: terminated.
02
Drugs
eprenetapopt
03
Conditions
esophageal carcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02999893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02999893.